Human pathogenic streptococcal proteomics and vaccine development

Authors

J. N. Cole, University of WollongongFollow
A. Henningham, University of WollongongFollow
C. M. Gillen, University of WollongongFollow
V. Ramachandran, University of WollongongFollow
Mark J. Walker, University of WollongongFollow

RIS ID

27094

Publication Details

This paper was originally published as Cole, JN, Henningham, A, Gillen, CM, Ramachandran, V and Walker, MJ, Human pathogenic streptococcal proteomics and vaccine development, Proteomics Clinical Applications, 2, 2008, 387-410. Copyright 2007 John Wiley & Sons. Journal information is available here.

Abstract

Gram-positive streptococci are non-motile, chain-forming bacteria commonly found in the normal oral and bowel flora of warm-blooded animals. Over the past decade, a proteomic approach combining 2-DE and MS has been used to systematically map the cellular, surface-associated and secreted proteins of human pathogenic streptococcal species. The public availability of complete streptococcal genomic sequences and the amalgamation of proteomic, genomic and bioinformatic technologies have recently facilitated the identification of novel streptococcal vaccine candidate antigens and therapeutic agents. The objective of this review is to examine the constituents of the streptococcal cell wall and secreted proteome, the mechanisms of transport of surface and secreted proteins, and describe the current methodologies employed for the identification of novel surface-displayed proteins and potential vaccine antigens.